BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25641331)

  • 1. Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis.
    Mancuso A; Mazzola A; Cabibbo G; Perricone G; Enea M; Galvano A; Zavaglia C; Belli L; Cammà C
    Dig Liver Dis; 2015 Apr; 47(4):324-30. PubMed ID: 25641331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
    Sotiropoulos GC; Nowak KW; Fouzas I; Vernadakis S; Kykalos S; Klein CG; Paul A
    Transplant Proc; 2012 Nov; 44(9):2754-6. PubMed ID: 23146514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study.
    Alsina AE; Makris A; Nenos V; Sucre E; Arrobas J; Franco E; Kemmer N
    Am Surg; 2014 Jul; 80(7):680-4. PubMed ID: 24987900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete Regression of Recurrent Advanced Hepatocellular Carcinoma After Liver Transplantation in Response to Sorafenib Treatment: A Case Report.
    Lee HY; Yang KH; Choi BH; Park YM; Yoon KT; Ryu JH; Chu CW
    Transplant Proc; 2016; 48(1):247-50. PubMed ID: 26915876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
    Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
    Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
    de'Angelis N; Landi F; Carra MC; Azoulay D
    World J Gastroenterol; 2015 Oct; 21(39):11185-98. PubMed ID: 26494973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation].
    Hu AB; He XS; Tai Q; Zhu XF; Ma Y; Wang DP; Wang GD; Wu LW; Ju WQ; Huang JF
    Zhonghua Yi Xue Za Zhi; 2012 May; 92(18):1264-7. PubMed ID: 22883065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Safety and efficacy of Sorafenib in treatment of tumor recurrence in liver transplantation recipients].
    Li XH; Zhong KB; Liu Y; Yang DH; Zhou J
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Sep; 31(9):1608-10. PubMed ID: 21945779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation.
    de'Angelis N; Landi F; Nencioni M; Palen A; Lahat E; Salloum C; Compagnon P; Lim C; Costentin C; Calderaro J; Luciani A; Feray C; Azoulay D
    Prog Transplant; 2016 Dec; 26(4):348-355. PubMed ID: 27555074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.
    Jia N; Liou I; Halldorson J; Carithers R; Perkins J; Reyes J; Yeh M; Stohr E; Rao S; Lin EH
    Anticancer Res; 2013 Jun; 33(6):2797-800. PubMed ID: 23749944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
    Sposito C; Mariani L; Germini A; Flores Reyes M; Bongini M; Grossi G; Bhoori S; Mazzaferro V
    J Hepatol; 2013 Jul; 59(1):59-66. PubMed ID: 23500153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
    Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
    Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation.
    Waghray A; Balci B; El-Gazzaz G; Kim R; Pelley R; Narayanan Menon KV; Estfan B; Romero-Marrero C; Aucejo F
    Clin Transplant; 2013; 27(4):555-61. PubMed ID: 23758296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation.
    Na GH; Hong TH; You YK; Kim DG
    World J Gastroenterol; 2016 Jul; 22(25):5790-9. PubMed ID: 27433092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
    Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
    World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
    Lei J; Zhong J; Hao J; Liu Z; Zhang P; Wu L; Yan L; Zhu J; Zeng Y; Li B; Wen T; Wang W
    Oncotarget; 2016 Jul; 7(27):42598-42607. PubMed ID: 26981887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
    Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
    Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
    Saab S; McTigue M; Finn RS; Busuttil RW
    Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.
    Barbier L; Fuks D; Pessaux P; Muscari F; Le Treut YP; Faivre S; Belghiti J
    Ann Surg Oncol; 2013 Oct; 20(11):3603-9. PubMed ID: 23715965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.